7,629.78

+49.71

+0.66%

52,279.93

+509.62

+0.98%

25,640.27

+203.27

+0.80%

2,839.99

+28.14

+1.00%

4.9060

-0.0230

-0.47%

18.60

-0.82

-4.22%

3,969.30

+70.40

+1.81%

77,280.34

-739.66

-0.95%

Crude Oil Dec 26

97.24

-6.88

-6.61%

US Private Equity

10,850.63

-82.20

-0.75%

NasdaqGS - Nasdaq Real Time Price USD

Gossamer Bio, Inc. (GOSS)

9.46 -0.92 (-8.86%)

As of 11:16:23 AM EST. Market Open.

Loading Chart for GOSS

Chart Range Bar

Interval:

In partnership with ChartIQ

Gossamer Bio (GOSS) Stock Sees Fair Value Lift As Analysts Weigh Seralutinib Risks

Gossamer Bio (GOSS) Stock Sees Fair Value Lift As Analysts Weigh Seralutinib Risks

Gossamer Bio (GOSS) Stock Draws Fresh Price Target Split Before Seralutinib NDA

Gossamer Bio (GOSS) Stock Draws Fresh Price Target Split Before Seralutinib NDA

Gossamer Bio Submits New Drug Application to U.S. FDA for Seralutinib for the Treatment of Pulmonary Arterial Hypertension

Gossamer Bio Submits New Drug Application to U.S. FDA for Seralutinib for the Treatment of Pulmonary Arterial Hypertension

Gossamer Bio Announces Effectiveness of 1-for-80 Reverse Stock Split

Gossamer Bio Announces Effectiveness of 1-for-80 Reverse Stock Split

Gossamer Bio to Present at Cantor Global Healthcare Conference

Gossamer Bio to Present at Cantor Global Healthcare Conference

Gossamer (GOSS) Announced Up to $250M of Financing, but Only $25M is Expected Upfront. Is the Runway Secure?

Gossamer (GOSS) Announced Up to $250M of Financing, but Only $25M is Expected Upfront. Is the Runway Secure?

Gossamer Bio announces $250m in funding to advance seralutinib

Gossamer Bio announces $250m in funding to advance seralutinib

Gossamer Bio Secures Up to $250 Million Private Placement to Fund Seralutinib Through Potential FDA Approval

Gossamer Bio Secures Up to $250 Million Private Placement to Fund Seralutinib Through Potential FDA Approval

Gossamer Bio Agrees to Up to $250 Million Private Placement; Shares Rise Pre-Bell

Gossamer Bio Agrees to Up to $250 Million Private Placement; Shares Rise Pre-Bell

Gossamer Bio Announces Up to $250 Million Structured Private Placement, Including $150 Million of Committed Capital, to Fund Seralutinib Through Potential FDA Approval

Gossamer Bio Announces Up to $250 Million Structured Private Placement, Including $150 Million of Committed Capital, to Fund Seralutinib Through Potential FDA Approval

Gossamer Bio (GOSS) Stock Sees Fair Value Cut As Analysts Split On Seralutinib

Gossamer Bio (GOSS) Stock Sees Fair Value Cut As Analysts Split On Seralutinib

Mobilize your Website

View Site in Mobile | Classic

Share by: